The European Generic Medicines Association (EGA) has expressed concerns over the European Commission’s policy regarding competition law investigations on patent settlements in pharmaceuticals, following the EC’s decision on the perindopril case.
The EC has imposed fines to the value of 427.7 million euros ($583 million) on French privately-held drugmaker Servier, and five producers of generic medicines (Niche/Unichem, Matrix, Teva, Krka and Lupin) for their deals to protect Servier’s blood pressure medicine perindopril from price competition from American generics companies.
European Commission vice-president Joaquín Almunia, in charge of competition policy, said: "Servier had a strategy to systematically buy out any competitive threats to make sure that they stayed out of the market. Such behavior is clearly anti-competitive and abusive. Competitors cannot agree to share markets or market rents instead of competing, even when these agreements are in the form of patent settlements. Such practices directly harm patients, national health systems and taxpayers. Pharmaceutical companies should focus their efforts on innovating and competing rather than attempting to extract extra rents from patients."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze